DUSP4 and hepatocellular carcinoma: Dual-specificity phosphatase 4 (DUSP4) inhibits sorafenib-induced ferroptosis in hepatocellular carcinoma by activating the RNA m6A reader, YTH N6-methyladenosine RNA binding protein C1 (YTHDC1), leading to enhanced expression of FTH and FTL[156].